Davis, Farchione and colleagues present the FDA’s evolving framework for psychedelic drug development in NEJM

FDA officials Davis, Farchione and colleagues outline what the agency calls its new framework for psychedelic drugs in a commentary published in the New England Journal of Medicine. The commentary begins with the U.S. mental health crisis, especially depression and PTSD, and identifies psychedelic compounds as a potential source of improved treatments. It reviews the history of psychedelic research and FDA actions supporting development, including Breakthrough Therapy designations, rolling review and priority review. The authors emphasize that psychedelic therapies remain investigational and that regulatory integration is still evolving. The framework reflects revisions to FDA’s 2023 draft guidance, informed by roughly 200 public comments and three additional years of experience with development programs. The supplied excerpt does not provide the framework’s detailed recommendations.